ArticleProceedings of the National Academy of Sciences of the United States of America2002
Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 115 citations in OpenAlex.
- Delineating the mechanism of fragility at BCL6 breakpoint region associated with translocations in diffuse large B cell lymphoma.Cellular and molecular life sciences : CMLS · 2024Article
- Article
- Rewiring cancer drivers to activate apoptosis.Nature · 2023Article
- The transcriptional program during germinal center reaction - a close view at GC B cells, Tfh cells and Tfr cells.Frontiers in immunology · 2023Review
- Mouse models of diffuse large B cell lymphoma.Frontiers in immunology · 2023Review
- BCL6 deletion in CD4 T cells does not affect Th2 effector mediated immunity in the skin.Immunology and cell biology · 2022Article
- Article
- Mouse Models of Germinal Center Derived B-Cell Lymphomas.Frontiers in immunology · 2021Review
- Article
- Article
- Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.Scientific reports · 2019Article
- MEF2B is a member of the BCL6 gene transcriptional complex and induces its expression in diffuse large B-cell lymphoma of the germinal center B-cell-like type.Laboratory investigation; a journal of technical methods and pathology · 2019Article
- Epigenetic Programing of B-Cell Lymphoma by BCL6 and Its Genetic Deregulation.Frontiers in cell and developmental biology · 2019Review
- Genetics of diffuse large B-cell lymphoma.Blood · 2018Review
- Review
- IL4 and IL21 cooperate to induce the high Bcl6 protein level required for germinal center formation.Immunology and cell biology · 2017Article
- Targeted epigenetic repression of a lymphoma oncogene by sequence-specific histone modifiers induces apoptosis in DLBCL.Leukemia & lymphoma · 2017Article
- PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.Oncotarget · 2016Article
- Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma.The Journal of biological chemistry · 2016Article
- The genetic landscape of diffuse large B-cell lymphoma.Seminars in hematology · 2015Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Thirty to forty percent of diffuse large B cell lymphomas (DLBCL) carry BCL-6 translocations that disrupt its 5' regulatory region. This same region is also subject to somatic hypermutations, although only a small fraction of these mutations have a detectable effect on transcription. Here, we show that transcription of the BCL-6 gene is negatively self-regulated in multiple cell types. This mechanism operates by means of the interaction of two BCL-6-binding sites within exon 1 of the gene and the BCL-6 protein itself, which is a potent transcription repressor. Because the DLBCL-associated "activating mutations" specifically target these exon 1 binding sites, and because the entire exon 1 is usually removed in the BCL-6-translocated tumors, this autoregulation is bypassed in 30-40% of all DLBCL cases. Our results not only demonstrate an important mechanism governing the expression of BCL-6, but also explain how BCL-6 is deregulated in a large number of DLBCL patients, providing a better understanding of BCL-6-related lymphomagenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.